Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-114 + S-1 in Advanced Solid Tumors
NCT02454062Phase 1Completed
- Sponsor
- Taiho Oncology
- Start
- Mar 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of TAS-114 in solid tumor (advanced stage) (2 arms), sponsored by Taiho Oncology. Primary endpoint: Maximum Tolerated Dose up to 2.5 Years. Started Mar 2013; status: completed.
02
Drugs
TAS-114
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02454062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454062.